Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma

OBJECTIVE To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Pati...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2009-09, Vol.104 (6), p.790-794
Main Authors: Soga, Norihito, Yamakado, Koichiro, Gohara, Hideo, Takaki, Haruyuki, Hiraki, Takao, Yamada, Tomomi, Arima, Kiminobu, Takeda, Kan, Kanazawa, Susumu, Sugimura, Yoshiki
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - secondary
Carcinoma, Renal Cell - surgery
Catheter Ablation - adverse effects
Catheter Ablation - methods
Diseases of the respiratory system
Female
Humans
Kidney Neoplasms
Kidneys
lung metastasis
Lung Neoplasms - mortality
Lung Neoplasms - secondary
Lung Neoplasms - surgery
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Palliative Care
percutaneous radiofrequency ablation
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
renal cell carcinoma
Retrospective Studies
Survival Rate
Treatment Outcome
Tumors of the urinary system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC). PATIENTS AND METHODS We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA. Patients with six or fewer lung metastases measuring ≤6 cm that were confined in the lung, had all lung tumours ablated (curative ablation). Patients with extrapulmonary lesions, seven or more lung tumours, or large tumours of >6 cm, had mass reduction (palliative ablation). The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence‐free survival in the curative ablation group. RESULTS There were significant differences in the overall survival rates between the curative and palliative groups at 1 year (100% vs 90%), 3 years (100% vs 52%) and 5 years (100% vs 52%) (P 
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2009.08459.x